Published Date: 08 Mar 2023
Italy's biggest conglomerate, Intesa Sanpaolo, has paid 360 million euros ($382 million) in cash to acquire a 26.2% stake in health insurer Intesa Sanpaolo RBM Salute, which it does not own. that it will be used.
Read Full NewsCould timing prostate cancer radiotherapy according to patients’ circadian rhythm genes reduce the risk for late side effects?
Progression-free survival with the multitarget PAM inhibitor approaches 10 months after anti-CDK4/6 and aromatase inhibitor failure.
Researchers retrospectively analyzed outcomes for 50 patients with biopsy-proven monoclonal gammopathy of renal significance for a median follow-up of 6.15 years.
In a small single-center study, 1-year survival is 100% among carefully selected patients who undergo bilateral lung transplantation for stage IV disease confined to the lungs.
1.
In Advanced Myxoid Liposarcoma, Is Trabectedin Winning?
2.
Gene Therapy for Hemophilia B Significantly Outperforms Factor IX Prophylaxis
3.
Mixed Results With Cyclophosphamide in Mismatched Unrelated Stem Cell Transplants
4.
Chemotherapy combination boosts overall survival in patients with EGFR-mutant non-small cell lung cancer
5.
Less Mental Decline With Darolutamide vs Enzalutamide in PC
1.
Innate Lymphoid Cells in Tumor Biology
2.
Modern Applications in Oncology in the Digital Era
3.
Omentum Cancer: Causes, Symptoms, and Treatment Options
4.
Hematologic Toxicity of CDK4/6 Inhibitors in Breast Cancer: Meta-Analysis and Safety Data
5.
Partial Gland Ablation in Prostate Cancer: Oncologic Outcomes in Intermediate-Risk Cases
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients
2.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- The Conclusion
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
5.
Should We Use DARA Up Front As First-Line Therapy in MM?
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation